{"id":"bc069c5c-674a-56ee-8180-d2ae69064e9f","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-valsartan-c0","predicate":"increases_in_recorded_comparison","statement":"Table 4 reports higher extrapolated valsartan C0 with RA, 25.8 versus 17.8 micromolar.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"d1b51823-68e2-5878-9f49-628ffa5cc46f","mechanism_event_label":"Table 4 reports higher extrapolated valsartan C0 with RA, 25.8 versus 17.8 micromolar.","subject":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"object":{"id":"c8de73d3-31dc-5c13-9730-3004db7be566","slug":"rat-valsartan-c0","display_name":"Rat extrapolated initial valsartan concentration","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"d1b51823-68e2-5878-9f49-628ffa5cc46f","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-valsartan-c0-event","event_type":"experimental_observation","label":"Table 4 reports higher extrapolated valsartan C0 with RA, 25.8 versus 17.8 micromolar.","description":"### ra-valsartan-c0\n\nTable 4 reports higher extrapolated valsartan C0 with RA, 25.8 versus 17.8 micromolar.\nEndpoint-specific discrepancy from the broad negative summary is preserved.\nModel and exposure: Same IV rat study; significant table marker, unlike AUC.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid. | 2021 | https://pubmed.ncbi.nlm.nih.gov/33435470/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC7828042/ | https://doi.org/10.3390/pharmaceutics13010083 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"RA plus valsartan","sequence_order":0,"notes":""},{"entity":{"id":"c8de73d3-31dc-5c13-9730-3004db7be566","slug":"rat-valsartan-c0","display_name":"Rat extrapolated initial valsartan concentration","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"increase","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_condition","value_text":"RA plus valsartan","comparator":"Valsartan alone","unit":null,"notes":"Condition belongs to the full experimental contrast; do not separate a joint intervention.","entity":{"slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"}},{"dimension":"experimental_condition","value_text":"3 mg/kg IV","comparator":"Valsartan alone","unit":null,"notes":"Condition belongs to the full experimental contrast; do not separate a joint intervention.","entity":{"slug":"valsartan","display_name":"Valsartan","entity_type_key":"drug"}},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"RA plus valsartan\", \"comparator\": \"Valsartan alone\", \"endpoint\": \"Table 4 reports higher extrapolated valsartan C0 with RA, 25.8 versus 17.8 micromolar.\", \"effect_direction\": \"increase\", \"combination\": \"joint\", \"conditions\": [{\"entity_slug\": \"rosmarinic-acid\", \"state\": \"RA plus valsartan\"}, {\"entity_slug\": \"valsartan\", \"state\": \"3 mg/kg IV\"}]}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"Same IV rat study; significant table marker, unlike AUC.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Rosmarinic acid collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Table 4 reports higher extrapolated valsartan C0 with RA, 25.8 versus 17.8 micromolar.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid. | https://pubmed.ncbi.nlm.nih.gov/33435470/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC7828042/ | https://doi.org/10.3390/pharmaceutics13010083","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference ra-valsartan-c0; Endpoint-specific discrepancy from the broad negative summary is preserved.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"7a3ac33d-194e-5fe0-b307-64300c6b71ae","evidence_kind":"source_excerpt","locator":"Lines 429-435","start_line":429,"end_line":435,"excerpt":"### ra-valsartan-c0\n\nTable 4 reports higher extrapolated valsartan C0 with RA, 25.8 versus 17.8 micromolar.\nEndpoint-specific discrepancy from the broad negative summary is preserved.\nModel and exposure: Same IV rat study; significant table marker, unlike AUC.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid. | 2021 | https://pubmed.ncbi.nlm.nih.gov/33435470/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC7828042/ | https://doi.org/10.3390/pharmaceutics13010083 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"Same IV rat study; significant table marker, unlike AUC.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"606cff22-a6ed-59cd-a84d-87f44c59dc25","stable_key":"import-ca8e9e6a-6953-51ec-b712-2b06398a416d","title":"Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"684b4eab1dc2c0057f679109770af0de9340af5cd933377b590298cf8a752956","revision_id":"4028d9c5-fb17-54c5-b72c-c6d21678a832","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}